Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2008-05-27
2008-05-27
Carlson, Karen Cochrane (Department: 1656)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Reexamination Certificate
active
10691125
ABSTRACT:
Compositions comprising PTH-rP peptides, combinations thereof, and multiepitope PTH-rP peptides, vectors for their delivery to antigen presenting cells, as well as methods are provided which are useful in the immunotherapy of parathyroid hormone related peptide expressing malignancies.
REFERENCES:
patent: 5114843 (1992-05-01), Rosenblatt et al.
patent: 5626845 (1997-05-01), Yoneda et al.
patent: 5880093 (1999-03-01), Bagnoli
patent: 5993817 (1999-11-01), Yoneda et al.
patent: 0822200 (1998-06-01), None
patent: WO 00/23594 (2000-04-01), None
patent: WO 00/61612 (2000-04-01), None
patent: WO 00/69900 (2000-11-01), None
patent: WO 01/81415 (2001-04-01), None
P. Correale, L. Michell, MT Del Vecchio, M. Sabatino, R. Petriolli, D. Pozzessere, S. Masili, G. Giorgi, L. Lozzi, P. Neri and G. Francini. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2. British Journal of Cancer 1722-1730 (2001).
G. Francini, A. Scardino, K. Kosmatopoulos, F. A. Lemonnier, G. Campoccia, M. Sabatino, D. Pozzessere, R. Petrioli, L. Lozzi, P. Neri, G. Fanetti, M.G. Cusi, and P. Correale. High-Affinity HLA-A(*)02.01 peptides from parathyroid hormone-related protein generate in vitro and in vivo antitumor CTL response without autoimmune side effects. The Journal of Immunology (2002).
P. Correale, M.G. Cusi, M. Sabatino, L. Micheli, D. Pozzessere, C. Nencini, P.E. Valensin, R. Petrioli, G. Giorgi, R. Zurbriggen, R. Gluck, G. Francini. Tumour-associated antigen (TAA)-specific cytotoxic T cell (CTL) reponse in vitro and in a mouse model, induced by TAA-plasmids delivered by influenza virosomes. European Journal of Cancer 37, 2097-2103 (2001).
L.J. Suva, G.A. Winslow, R.E. H. Wettenhall, R.G. Hammonds, J.M. Moseley, H. Diefenbach-Jagger, C.P. Rodda, B.E. Kemp, H. Rodriguez, E.Y. Chen, P.J. Hudson, T.J. Martin, W.I. Wood. A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science Reports, (Aug. 1987).
R.G. Fenton, D.D. Taub, L.W. Kwak, M.R. Smith, D. L. Longo. Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes. Journal of the Nat. Cancer Institute, vol. 85, No. 16, 1294-1302, (Aug. 1993).
S. Pascolo, N. Bervas, J.M. Ure, A.G. Smith, F.A. Lemonnier, and B. Peramau. HLA-A2.1-restricted education and cytolytic activity of CD8+ T lymphocytes from β2 microglobulin (β2m) HLA-A2.1 monochain transgenic H-2Dbβ2m double knockout mice. Journal Exp. Med., vol. 185, No. 12, 2043-2051, (Jun. 1997).
R.A. Henderson, H. Michel, K. Sakaguchi, J. Shabanowitz, E. Appella, D.F. Hunt, V.H. Engelhard. HLA-A2.1-associated peptides from a mutant cell line: A second pathway of antigen presentation. Science, vol. 225, (Mar. 1992).
D.F. Hunt, R.A. Henderson, J. Shabanowitz, K. Sakaguchi, H. Michel, N. Sevilir, A.L. Cox, E. Appella, V.H. Engelhard. Characterication of peptides bound to the Class I MHC Molecule HLA-A2.1 by mass spectrometry. Science, vol. 255, Issue 5049, 1261-1263, (Mar. 1992).
P. Correale, K. Walmsley, C. Neiroda, S. Zaremba, M. Zhu, J. Scholm and K.Y. Tsang. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. Journal of the National Cancer Institute, vol. 89, 293-300 (1997).
P. Correale, K. Walmsely, S. Zaremba, M. Zhu, J. Schlom, K.Y. Tsang. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. Journal of National Cancer Institute, 293-300, (Feb. 1997).
P. Correale, M. Sabatino, M.G. Cusi, L. Micheli, C. Nencini, D. Pozzessere, R. Petrioli, A. Aquino, L. DeVecchis, M. Turriziani, S.P. Prete, R. Sanguedolce, L. Rausa, G. Giorgi, G. Francini. In vitro generation of cytotoxic T lymphocytes against HLA-A2.1-restricted peptides derived from human thymidylate synthase. Journal of Chemotherapy. 519-26; (Oct. 2001).
T. Wolfel, E. Klehmann, C. Muller, K.H. Schutt, K.H. Meyer zum Buschenfelde and A. Knuth. Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. Journal of Experimental Medicine, vol. 170, 797-810, (1989).
J.P. Eder, P.W. Kantoff, K. Roper, G. Xu, G.J. Bubley, J. Boyden, L. Gritz, G. Mazzara, W.K. Oh, P. Arlen, K.Y. Tsang, D. Panicali, J. Schlom, and D.W. Kufe. A Phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clinical Cancer Research, vol. 6, 1632-1638, (May 2000).
C. Brander, O.O. Yang, N.G. Jones, Y. Lee, P. Goulder, R.P. Johnson, A. Trocha, D. Colbert, C. Hay, S. Buchbinder, C.C. Bergmann, H.J. Zweerink, S. Wolinsky, W.A. Blattner, S.A. Kalams and B.D. Walker. Efficient processing of the immundominant, HLA-A *0201-restricted human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitope despite multiple variations in the epitope flanking sequences. Journal of Virology, 10191-10198, (Dec. 1999).
M.R. Betts, J.P. Casazza, B.A. Patterson, S. Waldrop, W. Trigona, Tong-Ming Fu, F. Kern, LJ. Picker, and R.A. Koup. Putative Immunodominant human immunodeficiency virus-specific CD8+T-cell responses cannot be predicted by major histocompatibility complex class I haplotype. Journal of Virology, 9144-9151, (Oct. 2000).
S. Pascolo, N. Bervas, J.M. Ure, A.G. Smith, F.A. Lemmonnier, and B. Peramau. HLA-A2.1-restricted education and cytolytic activity of CD8+T lymphocytes fromβ2 microglobulin (β2m) HLA-A2.1 monochain transgenic H-2DD β2m double knockout mice. Journal of Experimental Medicine, vol. 185, No. 12, 2043-2051, (Jun. 1997).
K. Dunussi-Joannopoulos. Gene therapy vaccines: guiding the immune system to fight leukemia. The Journal of the Hellenic Society of Haematology, 124-134, (1999).
A. Zippelius, M.J. Pittet, P. Romero. Dissecting tumor antigen-specific CD8 T cell responses in cancer patients. Ludwig Institute for Cancer Research.
T.E. Sparer, S.G. Wynn, D.J. Clark, J.M. Kaplan, L.M. Cardoza, S.C. Wadsworth, A.E. Smith and L.R. Gooding. Generation of cytotoxic T lymphocytes against immunorecessive epitopes after multiple immunications with adenovirus vectors is dependent on haplotype. Journal of Virology, 2277-2284, (Mar. 1997).
G.R. Mundy and T.A. Guise. Role of parathyroid hormone-related peptide in hypercalcemia of malignancy and osteolytic bone disease. Endocrine-Related Cancer, 15-26, (1998).
T. Takeshita, H. Takahashi, S. Kozlowski, J.D. Ahlers, C.D. Pendleton, R.L. Moore, Y. Nakagawa, K. Yokomuro, B.S. Fox, D.H. Margulies, and J.A. Berzofsky. Molecular analysis of the same HIV peptide functionally binding to both a Class I and a Class II MHC molecule. The American Association of Immunologists, (1995).
V. Tsai, S. Southwood, J. Sidney, K. Sakaguchi, Y. Kawakami, E. Appella, A. Sette, and E. Celis. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunication with peptide-pulsed dendritic cells. The Journal of Immunology, vol. 158: 1796-1802, (1997).
D.M. Pardoll. (Commentary) Inducing autoimmune disease to treat cancer. Proc. Natl. Acad. Sci. USA, vol. 96, 5340-5342, (May 1999).
D. O'Sullivan, T. Arrhenius, J. Sidney, Marie-France Del Guercio, M. Albertson, M. Wall, C. Oseroff, S. Southwood, S.M. Colon, Federico C.A. Gaeta, and A. Sette. On the interaction of promiscuous antigen peptides with different dr alleles. The Journal of Immunology, vol. 147, 2663-2669, No. 8, (Oct. 1991).
A. Heiser, P. Dahm, D.R. Yancy, M.A. Maurice, D. Boczkowski, S.K. Nair, E. Gilboa, and J. Vieweg. Human dendritic cells trasfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. The Journal of Immunology, 164: 5508-5514 (2000).
S.A. Thomson, R. Khanna, J. Gardner, S.R. Burrows, B. Coupar, D.J. Moss and A. Suhrbier. Minimal epitopes expresse
Correale Pierpaolo
Cusi Maria Grazia
Francini Guido
Pevion Biotech, Ltd.
Proskauer Rose LLP
Rooke Agnes B.
LandOfFree
PTH-rP related peptide cancer therapeutics does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with PTH-rP related peptide cancer therapeutics, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PTH-rP related peptide cancer therapeutics will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3913109